115 related articles for article (PubMed ID: 9138599)
1. Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells.
Silvestrini R; Gornati D; Zaffaroni N; Bearzatto A; De Marco C
Breast Cancer Res Treat; 1997 Jan; 42(2):103-12. PubMed ID: 9138599
[TBL] [Abstract][Full Text] [Related]
2. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
Berruti A; Bitossi R; Gorzegno G; Bottini A; Alquati P; De Matteis A; Nuzzo F; Giardina G; Danese S; De Lena M; Lorusso V; Farris A; Sarobba MG; DeFabiani E; Bonazzi G; Castiglione F; Bumma C; Moro G; Bruzzi P; Dogliotti L;
J Clin Oncol; 2002 Oct; 20(20):4150-9. PubMed ID: 12377958
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).
Gebbia V; Borsellino N; Testa A; Latteri MA; Milia V; Valdesi M; Giotta F; Gebbia N; Colucci G
Anticancer Drugs; 1997 Nov; 8(10):943-8. PubMed ID: 9436637
[TBL] [Abstract][Full Text] [Related]
4. In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells.
Villa R; Zaffaroni N; Orlandi L; Bearzatto A; Costa A; Silvestrini R
Eur J Cancer; 1994; 30A(10):1534-40. PubMed ID: 7833114
[TBL] [Abstract][Full Text] [Related]
5. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
Dogliotti L; Berruti A; Buniva T; Zola P; Baù MG; Farris A; Sarobba MG; Bottini A; Alquati P; Deltetto F; Gosso P; Monzeglio C; Moro G; Sussio M; Perroni D
J Clin Oncol; 1996 Apr; 14(4):1165-72. PubMed ID: 8648371
[TBL] [Abstract][Full Text] [Related]
6. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
De Lena M; Lorusso V; Bottalico C; Brandi M; De Mitrio A; Catino A; Guida M; Latorre A; Leone B; Vallejo C; Gargano G
J Clin Oncol; 1997 Oct; 15(10):3208-13. PubMed ID: 9336357
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
Ianniello GP; De Cataldis G; Comella P; Scarpati MD; Maiorino A; Brancaccio L; Cioffi R; Lombardi A; Carnicelli P; Tinessa V
Cancer; 1996 Jul; 78(1):63-9. PubMed ID: 8646728
[TBL] [Abstract][Full Text] [Related]
8. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells.
Villa R; Orlandi L; Berruti A; Dogliotti L; Zaffaroni N
Int J Oncol; 1999 Jan; 14(1):133-8. PubMed ID: 9863019
[TBL] [Abstract][Full Text] [Related]
9. Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis.
Orlandi L; Zaffaroni N; Bearzatto A; Villa R; De Marco C; Silvestrini R
Int J Cancer; 1998 Oct; 78(3):377-84. PubMed ID: 9766575
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells.
Silvestrini R; Zaffaroni N; Villa R; Orlandi L; Costa A
Int J Cancer; 1992 Nov; 52(5):813-7. PubMed ID: 1428236
[TBL] [Abstract][Full Text] [Related]
11. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
[TBL] [Abstract][Full Text] [Related]
12. Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.
Lopez M; Vici P; Di Lauro L; Paoletti G; Gionfra T; Conti F; Carpano S; Pignatti F; Giannarelli D
Eur J Cancer; 1995 Sep; 31A(10):1611-4. PubMed ID: 7488410
[TBL] [Abstract][Full Text] [Related]
13. Schedule-dependent modulation of idarubicin cytotoxicity by lonidamine in human lymphoma cell lines.
Zaffaroni N; Villa R; Gornati D; Folini M; Silvestrini R
Int J Oncol; 1997 Oct; 11(4):675-9. PubMed ID: 21528260
[TBL] [Abstract][Full Text] [Related]
14. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
Pacini P; Rinaldini M; Algeri R; Guarneri A; Tucci E; Barsanti G; Neri B; Bastiani P; Marzano S; Fallai C
Eur J Cancer; 2000 May; 36(8):966-75. PubMed ID: 10885599
[TBL] [Abstract][Full Text] [Related]
15. Weekly epirubicin plus lonidamine in advanced breast carcinoma.
Nisticò C; Garufi C; Milella M; D'Ottavio AM; Vaccaro A; Fabi A; Terzoli E
Breast Cancer Res Treat; 1999 Aug; 56(3):233-7. PubMed ID: 10573114
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of antiproliferative drug activity by lonidamine in hepatocellular carcinoma cells.
Ricotti L; Tesei A; De Paola F; Milandri C; Amadori D; Frassineti GL; Ulivi P; Zoli W
J Chemother; 2003 Oct; 15(5):480-7. PubMed ID: 14598941
[TBL] [Abstract][Full Text] [Related]
17. In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines.
Savini S; Zoli W; Nanni O; Volpi A; Frassineti GL; Magni E; Flamigni A; Amadori A; Amadori D
Breast Cancer Res Treat; 1992; 24(1):27-34. PubMed ID: 1463869
[TBL] [Abstract][Full Text] [Related]
18. In vitro potentiation by lonidamine of the sc-RIP saporin 6 effect in a human metastatic breast cancer cell line.
Roncuzzi L; Zoli W; Bajorko P; Gasperi-Campani A
Anticancer Res; 1995; 15(3):773-6. PubMed ID: 7645957
[TBL] [Abstract][Full Text] [Related]
19. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
20. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Cortesi E; Cammilluzzi E; Antimi M; Terzoli E; Lepidini G; Vici P; Barone C; Ferretti G; Di Cosimo S; Nistico C; Carlini P; Conti F; Di Lauro L; Botti C; Vitucci C; Fabi A; Giannarelli D; Marolla P
J Clin Oncol; 2003 Sep; 21(18):3462-8. PubMed ID: 12972521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]